Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00421317
Status:
TERMINATED
Last Update Posted:
2016-01-06
First Post:
2007-01-09
Brief Title:
Imatinib in Adult Patients With Metastatic Ocular Melanoma
Sponsor:
Centre Oscar Lambret
Organization:
Centre Oscar Lambret
Study Overview
Official Title:
A Phase II Multicentric Trial to Assess Efficacy and Toxicity of Imatinib in Adult Patients With Metastatic Ocular Melanoma
Status:
TERMINATED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study stopped at the end of the first step
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
O-Mel-Inib
Brief Summary:
The scope of the trial is to determinate the anti-tumoral activity of imatinib in metastatic ocular melanoma patients
Detailed Description:
Further study details as provided by Centre Oscar Lambret
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None